BioNeutral Group Achieves EPA Approval for Its Ygiene™ Disinfectant

Newark, NJ, February 28, 2011

BioNeutral Group Inc.a  speciality life science technology-based company, today announced that it has received approval and registration from the Environmental Protection Agency (EPA) in response to the Company's regulatory application for its Ygiene™ 206.

In order to obtain regulatory approval for its hospital and industrial grade line of products to be used as high level disinfectant and sterilants, in August 2010, following several years of research and development under the direction of the BioNeutral Chief Scientist Andrew Kielbania, PhD, and in collaboration with Dr. Philip Tierno, PhD, Chairman of its scientific advisory board, BioNeutral submitted an extensive EPA application along with the required independent GLP laboratory testing results.

"The EPA's approval of BioNeutral's Ygiene™ disinfectant is very welcome news, said Dr. Philip Tierno, Jr. PhD, Director of Clinical Microbiology & Immunology at New York University Langone Medical Center and Clinical Professor of Microbiology & Pathology at New York University School of Medicine.  "Ygiene™ will now give hospitals a far more powerful, yet much safer alternative to bleach, and to fight the ever increasing array of super-bugs in their environment".

"We are all extremely pleased", stated Dr. Andy Kielbania, Chief Scientist at BioNeutral Group, "This EPA approval is a milestone in the validation of our Ygiene™ technology and all of the various product line it encompasses.  We are now extremely well positioned to proceed with vigor in making both our complementary platforms Ogiene™ and Ygiene™ products available to all".